<DOC>
	<DOC>NCT02737319</DOC>
	<brief_summary>The investigators analyzed the HMG-CoA reductase inhibitor, rosuvastatin, for the prevention of contrast-medium-induced nephropathy in patients undergoing primary angioplasty.</brief_summary>
	<brief_title>A Randomized Trial of Rosuvastatin in Elective Angioplasty to Prevent Contrast-induced Nephropathy (CLEAR-CIN).</brief_title>
	<detailed_description>Patients with stable coronary artery disease already taking chronic statin undergoing elective angioplasty are at risk for contrast-medium-induced nephropathy because there are specified risk factors as age more than 75 years, chronic renal insufficiency, diabetes, use of contrast and the lack of effective prophylaxis.</detailed_description>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Rosuvastatin Calcium</mesh_term>
	<criteria>chronic statin use positive stress test findings (electrocardiography, nuclear imaging, or stress echocardiography elective angioplasty. nonstatin therapy any presentation of ACS within 24 hours before the time of randomization current use of potent CYP3A4 inhibitors, including azole antifungals, protease inhibitors, macrolide antibiotics, and cyclosporine renal replacement therapy, a history of kidney transplant, pregnant and with renal failure (serum creatinine &gt; 3.0 mg/dl).</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Contrast,nephropathy, angioplasty, stable coronary</keyword>
</DOC>